Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Shares Bought by Van ECK Associates Corp

Van ECK Associates Corp raised its stake in Tandem Diabetes Care, Inc. (NASDAQ:TNDM) by 28.1% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 4,901 shares of the medical device company’s stock after purchasing an additional 1,074 shares during the quarter. Van ECK Associates Corp’s holdings in Tandem Diabetes Care were worth $177,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in TNDM. Brooklyn Investment Group acquired a new position in shares of Tandem Diabetes Care during the 3rd quarter valued at $28,000. Assetmark Inc. acquired a new position in shares of Tandem Diabetes Care during the 3rd quarter valued at $29,000. McIlrath & Eck LLC acquired a new position in shares of Tandem Diabetes Care during the 3rd quarter valued at $52,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Tandem Diabetes Care during the 3rd quarter valued at $105,000. Finally, Stonehage Fleming Financial Services Holdings Ltd acquired a new position in shares of Tandem Diabetes Care during the 4th quarter valued at $92,000.

Analyst Upgrades and Downgrades

TNDM has been the topic of several recent research reports. Robert W. Baird reduced their target price on shares of Tandem Diabetes Care from $39.00 to $37.00 and set a “neutral” rating on the stock in a report on Thursday, November 7th. Morgan Stanley upgraded shares of Tandem Diabetes Care from an “equal weight” rating to an “overweight” rating and set a $45.00 target price on the stock in a report on Monday, December 2nd. Sanford C. Bernstein assumed coverage on shares of Tandem Diabetes Care in a report on Wednesday, November 6th. They set an “outperform” rating and a $42.00 target price on the stock. Barclays boosted their price objective on shares of Tandem Diabetes Care from $58.00 to $60.00 and gave the stock an “overweight” rating in a report on Friday, November 8th. Finally, Citigroup cut their price objective on shares of Tandem Diabetes Care from $57.00 to $50.00 and set a “buy” rating on the stock in a report on Wednesday, December 11th. Four investment analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. Based on data from MarketBeat, Tandem Diabetes Care presently has a consensus rating of “Moderate Buy” and a consensus target price of $53.81.

Tandem Diabetes Care Price Performance

TNDM opened at $31.00 on Monday. The company has a 50-day moving average of $35.48 and a 200-day moving average of $36.70. The company has a market capitalization of $2.04 billion, a P/E ratio of -16.06 and a beta of 1.32. Tandem Diabetes Care, Inc. has a 1-year low of $24.42 and a 1-year high of $53.69. The company has a debt-to-equity ratio of 1.29, a quick ratio of 2.32 and a current ratio of 2.90.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.